Emergent Biosolutions Inc.
| NYSE: EBS | Healthcare / Drug Manufacturers / USA |
| 3.26 | -0.1800 | -5.23% | Vol 1.50M | 1Y Perf -83.73% |
| Sep 22nd, 2023 16:00 DELAYED |
| BID | 3.21 | ASK | 3.27 | ||
| Open | 3.44 | Previous Close | 3.44 | ||
| Pre-Market | - | After-Market | 3.24 | ||
| - - | -0.02 -0.61% |
| Target Price | 36.50 | Analyst Rating | Hold 3.00 | |
| Potential % | 1.02K | Finscreener Ranking | ★★★+ 50.57 | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-33 | Value Ranking | ★★★+ 54.40 | |
| Insiders Value % 3/6/12 mo. | -100/-100/2 | Growth Ranking | ★★★★ 57.52 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-3 | Income Ranking | — - | |
| Price Range Ratio 52W % | -0.74 | Earnings Rating | Strong Sell | |
| Market Cap | 168.89M | Earnings Date | 14th Nov 2023 | |
| Alpha | -0.04 | Standard Deviation | 0.15 | |
| Beta | 0.88 |
Today's Price Range 3.203.47 | 52W Range 3.4022.35 | 5 Year PE Ratio Range 5.30133.60 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -17.88% | ||
| 1 Month | -28.04% | ||
| 3 Months | -65.02% | ||
| 6 Months | -58.52% | ||
| 1 Year | -83.73% | ||
| 3 Years | -96.81% | ||
| 5 Years | -95.06% | ||
| 10 Years | -83.22% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 10.61 | |||
ROE last 12 Months | 3.91 | |||
ROA (5Y Avg) | 4.16 | |||
ROA last 12 Months | 2.00 | |||
ROC (5Y Avg) | 8.58 | |||
ROC last 12 Months | 3.02 | |||
Return on invested Capital Q | -2.92 | |||
Return on invested Capital Y | 8.10 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 3.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 17.40 | ||||
| 0.47 | ||||
| 0.83 | ||||
| 3.40 | ||||
| -3.10 | ||||
| 3.96 | ||||
| 1.35 | ||||
| 29.05 | ||||
| 1.49B | ||||
| Forward PE | 1.89 | |||
| PEG | 2.85 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.60 | ||||
| 4.20 | ||||
| 0.42 | ||||
| 0.73 | ||||
| 4.50 | ||||
| Leverage Ratio | 1.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 58.10 | ||||
| 9.90 | ||||
| 19.00 | ||||
| 20.30 | ||||
| -17.19 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 790.20M | ||||
| 15.84 | ||||
| 25.09 | ||||
| 30.25 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.98 | -1.06 | -8.16 |
| Q01 2023 | -1.67 | -3.17 | -89.82 |
| Q04 2022 | 0.32 | -0.31 | -196.88 |
| Q03 2022 | -0.06 | -1.27 | -2 016.67 |
| Q02 2022 | 0.63 | -0.86 | -236.51 |
| Q01 2022 | 0.24 | 0.18 | -25.00 |
| Q04 2021 | 3.89 | 4.50 | 15.68 |
| Q03 2021 | 2.03 | -0.36 | -117.73 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | 0.05 | -91.53 | Negative |
| 12/2023 QR | 0.94 | -52.76 | Negative |
| 12/2023 FY | -3.24 | -117.45 | Negative |
| 12/2024 FY | 2.10 | 940.00 | Positive |
| Next Report Date | 14th Nov 2023 |
| Estimated EPS Next Report | 0.05 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.50M |
| Shares Outstanding | 51.81K |
| Shares Float | 46.63M |
| Trades Count | 7.88K |
| Dollar Volume | 4.88M |
| Avg. Volume | 3.31M |
| Avg. Weekly Volume | 4.07M |
| Avg. Monthly Volume | 3.60M |
| Avg. Quarterly Volume | 2.24M |
Emergent Biosolutions Inc. (NYSE: EBS) stock closed at 3.26 per share at the end of the most recent trading day (a -5.23% change compared to the prior day closing price) with a volume of 1.50M shares and market capitalization of 168.89M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 2200 people. Emergent Biosolutions Inc. CEO is Robert G. Kramer.
The one-year performance of Emergent Biosolutions Inc. stock is -83.73%, while year-to-date (YTD) performance is -72.4%. EBS stock has a five-year performance of -95.06%. Its 52-week range is between 3.4 and 22.35, which gives EBS stock a 52-week price range ratio of -0.74%
Emergent Biosolutions Inc. currently has a PE ratio of 17.40, a price-to-book (PB) ratio of 0.47, a price-to-sale (PS) ratio of 0.83, a price to cashflow ratio of 3.40, a PEG ratio of 2.85, a ROA of 2.00%, a ROC of 3.02% and a ROE of 3.91%. The company’s profit margin is -17.19%, its EBITDA margin is 19.00%, and its revenue ttm is $790.20 Million , which makes it $15.84 revenue per share.
Of the last four earnings reports from Emergent Biosolutions Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $0.05 for the next earnings report. Emergent Biosolutions Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for Emergent Biosolutions Inc. is Hold (3), with a target price of $36.5, which is +1 019.63% compared to the current price. The earnings rating for Emergent Biosolutions Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Emergent Biosolutions Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Emergent Biosolutions Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.43, ATR14 : 0.38, CCI20 : -158.84, Chaikin Money Flow : -0.25, MACD : -0.56, Money Flow Index : 13.51, ROC : -28.82, RSI : 26.96, STOCH (14,3) : 2.99, STOCH RSI : 0.00, UO : 35.44, Williams %R : -97.01), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Emergent Biosolutions Inc. in the last 12-months were: Ronald B. Richard (Sold 1 912 shares of value $22 829 ), Zoon Kathryn C (Sold 3 530 shares of value $29 526 )
Emergent Biosolutions Inc.
Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products.
CEO: Robert G. Kramer
Telephone: +1 240 631-3200
Address: 400 Professional Drive, Gaithersburg 21079, MD, US
Number of employees: 2 200
